![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pharma Blog Watch
Pharma Blog Watch
Generics
Threaten J&J (PharmaGossip)
In this post, the pharma insider discusses recent approvals of generic versions
of Johnson & Johnson (J&J) products, including one for Tevas version
of Risperdal. However, [t]he most pressing threat to [J&Js]
business came from Mylan Laboratories, which last month won U.S. approval to
sell generic versions of three Topamax doses with combined annual sales of approximately
$1.4 billion.
The drugmaker has responded by attempting to block the launch of Mylans product. As the first to file for approval of generic Topamax, Mylan has six months exclusivity in the marketplace so could reap a rich harvest before other generics enter the field.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct